Daiichi Sankyo voluntarily placed a partial hold on recruitment in the phase‑III IDeate‑Lung02 study of the antibody‑drug conjugate ifinatamab deruxtecan after a higher‑than‑expected incidence of grade‑5 interstitial lung disease events, the company told BioWorld. The move affects ongoing enrollment and will prompt investigators and regulators to review safety signals tied to pulmonary toxicity. The company did not disclose the number of deaths but said it paused to reassess risk mitigation and monitoring procedures. The pause underscores persistent safety risks with ADCs that carry cytotoxic payloads and will affect timelines for potential approvals and partner discussions.